Evidence map›Paper›PMID 40746413›Full record

ReviewMediators of inflammation2025

Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma.

Joanna Wieczfinska, Rafal Pawliczak

Abstract readReview
In one paragraph

Review in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joanna WieczfinskaDepartment of Immunopathology, Medical Faculty, Medical University of Lodz, Lodz, Poland.ORCID https://orcid.org/0000-0002-8830-1507
Rafal PawliczakDepartment of Immunopathology, Medical Faculty, Medical University of Lodz, Lodz, Poland.ORCID https://orcid.org/0000-0001-6784-453X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the main causes of the exacerbation of chronic airway inflammatory diseases is respiratory virus infections. The most prevalent viruses that can infect humans multiple times a year are rhinovirus (RV) and respiratory syncytial virus (RSV). Because remodeling factors like matrix metalloproteinases (MMPs), which are released by infiltrating neutrophils, are present. Airway remodeling is a characteristic of the pathology of airway diseases such as bronchial asthma. In these circumstances, viral infections may result in increased neutrophilic activation, which would exacerbate asthma symptoms and modify the airway. Although a connection between viral infections and acute exacerbations of chronic inflammatory respiratory diseases has been established, anti-inflammatory medications are frequently used in conjunction with antiviral medications to treat viral infections. Although their modes of action differ, they all lessen inflammation, which is essential for the development of airway remodeling. This review addresses the potential role of anti-inflammatory and antiviral drugs in preventing airway remodeling.

Indexed as

Airway RemodelingAntiviral AgentsAsthmaVirus DiseasesAnimalsAnti-Inflammatory AgentsHumansRhinovirusAnti-Inflammatory AgentsAntiviral Agentsairway remodelinganti-inflammatory drugsinflammationviral infection

Identifiers

PMID40746413
PMCPMC12313378

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.